Skip to content

miRNA as a Novel Toxicity Biomarker

Available On Demand

Speakers

Juan J. Díaz-Mochón

Juan J. Díaz-Mochón, Ph.D.

Chief Executive Officer,
DESTINA Genomics Ltd 

Anitaben Tailor

Anitaben Tailor, Ph.D.

Biology Technical Marketing Manager, Merck KGaA, Darmstadt, Germany

After earning a PhD in Medicinal Chemistry at the Universidad de Granada, Juan J. Díaz-Mochón was a Postdoctoral Research Associate at the University of Southampton and the University of Edinburgh. He then joined Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research. In 2017, he established DESTINA Genomics Ltd., focusing on highly specific nucleic acid detection, and is currently the Executive Director and CEO.

Speaker Bio

Anitaben Tailor earned a Master's in Pharmacology at King’s College London, then a PhD in Biochemical Immunopharmacology at the University of London. Following her Postdoc at Louisiana State University, she held faculty positions at Johns Hopkins University and the NIH. In 2009, Anita joined industry as a Field Application Scientist and was later appointed SMC® Technology and Application lead. She is now in Biology Technical Marketing, focusing on immunoassays within Pharma/CROs.

Speaker Bio

Toxicity affects all facets of drug development. A guiding tenet in toxicity studies is to eliminate drug candidates that cause toxicity as early as possible. It is critical to identify biomarkers that are not only organ- or tissue-specific but also sensitive enough to identify damage before it becomes extensive.

microRNAs (miRNAs) fulfill the criteria for an ideal biomarker and show superior sensitivity compared to enzyme-based biomarkers.

Join this webinar to explore how to overcome sample prep and amplification challenges associated with miRNAs to get accurate ultrasensitive quantification without PCR. See how combining high-sensitivity immunoassays with cutting-edge miRNA detection technology empowers you to detect miRNA in biofluids with better reproducibility and ease of use.

You'll also discover why miR-122 has emerged as a novel biomarker for early detection of liver injury and explore the benefits of using it to evaluate drug safety profiles in the early stages of drug development such as minimizing financial loss due to late-stage drug failure.

In this webinar, you will learn:

  • What makes miRNA a suitable biomarker for liver toxicity studies and its role in drug development;
  • Why immunoassays are a critical tool in organ toxicity studies;
  • How the latest technology enables early and accurate detection of
    low-abundant liver toxicity biomarkers.
For Research Use Only. Not For Use In Diagnostic Procedures.

Webinar brought to you by


This webinar is sponsored by Merck KGaA, Darmstadt, Germany. MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

Enter your details to view this webinar on-demand

[Merck] 26-Jul-22 miRNA as a Novel Toxicity Biomarker

  • Do you have any immediate interest in purchasing or learning more about immunoassays for your toxicity research?
  • Do you study or plan to use miRNA as a biomarker in your research?
  • By registering you agree that Merck KGaA, Darmstadt, Germany and Bitesize Bio may contact you in the future with follow up material about this webinar and other related information. You can unsubscribe with one click at any time.
  • This field is for validation purposes and should be left unchanged.

All emails contain an unsubscribe link. You can review our privacy policy, cookie policy and terms and conditions online.

Share this to your network:
LinkedIn
Scroll To Top